SciClone doses the first patient in a phase 3 clinical trial for the treatment of lung cancer in China







Newswires MT 2022

All the latest news from SCICLONE PHARMACEUTICALS (HOLDINGS) LIMITED

2022 sales 2,839 million
409M
409M
2022 net income 905M
130M
130M
Net cash 2022 1,516 million
219M
219M
PER 2022 ratio 4.53x
2022 return 5.18%
Capitalization 4,062 million
586M
586M
EV / Sales 2022 0.90x
EV / Sales 2023 0.69x
# of employees 950
Floating 62.0%

Chart SCICLONE PHARMACEUTICALS (HOLDINGS) LIMITED


Duration :

Period :




SciClone Pharmaceuticals (Holdings) Limited Technical Analysis Chart |  MarketScreener

Technical Analysis Trends SCICLONE PHARMACEUTICALS (HOLDINGS) LIMITED

Short term Middle term Long term
Tendencies Bearish Bearish Bearish




Evolution of the income statement

Sale

To buy

Medium consensus SURPASS
Number of analysts 3
Last closing price CNY5.98
Average target price CNY9.74
Average Spread / Target 62.8%


Comments are closed.